两种阿尔茨海默氏病的药物慢化了早期疾病,但带来风险和成本,而新的血液测试可以提前发现。 Two Alzheimer’s drugs slow early disease but carry risks and cost, while a new blood test enables earlier detection.

Donanemab和Lecanemab这两种新的阿尔茨海默氏病新药(Donanemab和Lecanemab)在减缓早期疾病蔓延方面成效不大,但冒着脑出血等风险,而且费用高昂,导致一些国家的核准和报销有限。 Two new Alzheimer’s drugs, donanemab and lecanemab, show modest success in slowing early-stage disease progression but carry risks like brain bleeding and are costly, leading to limited approval and reimbursement in some countries. 经美国批准的血液测试可以更早地检测到阿尔茨海默氏氏生物标记,尽管欧洲专家仍然将临床评估与检测放在优先地位。 A U.S.-approved blood test can detect Alzheimer’s biomarkers earlier, though European experts still prioritize clinical evaluation alongside testing. 近一半的病例与吸烟、肥胖和无活动等可改变的风险有关,但生活方式干预措施在试验中成效有限。 Nearly half of cases are linked to modifiable risks like smoking, obesity, and inactivity, yet lifestyle interventions have had limited success in trials. 尽管取得了逐步的进展,但专家们认为,在经历了几十年的停滞之后,哪怕是微小的成果也是巨大的,他们强调早期发现和长期研究是未来突破的关键。 Despite incremental progress, experts view even small gains as significant after decades of stagnation, emphasizing early detection and long-term research as key to future breakthroughs.